Sidney Kimmel – Jefferson joins Driver network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Sidney Kimmel Cancer Center – Jefferson Health announced a collaboration with Driver, a first-of-its-kind global technology platform that connects cancer patients to the best treatments, which has launched in the United States and China.

Driver’s platform enables any patient, anywhere in the world, to access treatment options across an unprecedented network of cancer centers without leaving home.

NCI and the Chinese National Cancer Center are the founding members of Driver’s global network. To date, more than thirty leading cancer centers in addition to SKCC comprise Driver’s network, including the Cleveland Clinic; Mayo Clinic; Massachusetts General Hospital; University of California, San Francisco; University of California, Los Angeles; Duke University; University of North Carolina; and Emory.

In order to provide patients with extensive cancer treatment options and information, Driver processes medical records and tumor data, then offers current evidence-based treatment guidelines as well as information on clinical trials for which a patient is potentially eligible that are being offered at any of the cancer centers in Driver’s network.

Driver’s lead investor is Horizons Ventures, with whom Driver has partnered from its inception to build its platform in China in parallel to the United States.

YOU MAY BE INTERESTED IN

When our hematological malignancy testing pilot project began in Eldoret, Kenya, there seemed to be a mismatch in relation to progress in healthcare. The region, like much of sub-Saharan Africa, had been focusing on combatting infectious diseases such as HIV and malaria—which was much-needed—yet cancer care was under-resourced. 
Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research. 
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login